Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds
US-11085015-B2 · Aug 10, 2021 · US
US11932845B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11932845-B2 |
| Application number | US-201314405390-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 3, 2013 |
| Priority date | Jun 4, 2012 |
| Publication date | Mar 19, 2024 |
| Grant date | Mar 19, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides non-naturally occurring microbial organisms having a 4-hydroxybutyrate, 1,4-butanediol, or other product pathway and being capable of producing 4-hydroxybutyrate, 1,4-butanediol, or other product, wherein the microbial organism comprises one or more genetic modifications. The invention additionally provides methods of producing 4-hydroxybutyrate, 1,4-butanediol, or other product or related products using the microbial organisms.
Opening claim text (preview).
What is claimed is: 1. A non-naturally occurring microbial organism, said microbial organism having a 4-hydroxybutyrate pathway and being capable of producing 4-hydroxybutyrate, wherein said microbial organism comprises a genetic modification that increases expression of a gamma-butyrolactone esterase relative to the microbial organism in the absence of the genetic modification to increase expression of a gamma-butyrolactone esterase, wherein the gamma-butyrolactone esterase converts gamma-butyrolactone to 4-hydroxybutyrate and decreases production of gamma-butyrolactone relative to the microbial organism in the absence of the genetic modification to increase expression of a gamma-butyrolactone esterase, wherein the gamma-butyrolactone esterase is expressed in a sufficient amount to produce 4-hydroxybutyrate, and wherein the microbial organism comprises a genetic modification that decreases expression of an alcohol dehydrogenase relative to the microbial organism in the absence of the genetic modification to decrease expression of an alcohol dehydrogenase. 2. The microbial organism of claim 1 , wherein said microbial organism further comprises a genetic modification selected from: (A) a genetic modification that increases expression of phosphoenolpyruvate carboxylase relative to the microbial organism in the absence of the genetic modification; (B) a genetic modification that increases expression of alpha-ketoglutarate dehydrogenase relative to the microbial organism in the absence of the genetic modification; (C) a genetic modification that increases expression of a non-phosphotransferase (PTS) glucose uptake system relative to the microbial organism in the absence of the genetic modification; (D) a genetic modification that decreases expression of succinyl-CoA synthetase relative to the microbial organism in the absence of the genetic modification; (E) a genetic modification that decreases expression of an acyl coenzyme A thioesterase relative to the microbial organism in the absence of the genetic modification; (F) a genetic modification that decreases expression of a non-energy-producing NADH dehydrogenase relative to the microbial organism in the absence of the genetic modification; (G) a genetic modification that decreases expression of a cytochrome oxidase relative to the microbial organism in the absence of the genetic modification; and (H) a combination of two or more, three or more, four or more, five or more, six or all of the genetic modifications of parts (A)-(G). 3. The microbial organism of claim 1 , wherein said microbial organism further comprises a 4-hydroxybutyryl-CoA pathway. 4. The microbial organism of claim 1 , wherein said microbial organism further comprises a 1,4-butanediol pathway. 5. The microbial organism of claim 1 , further comprising a genetic modification selected from: (i) a genetic modification that increases expression of pyruvate dehydrogenase relative to the microbial organism in the absence of the genetic modification; (ii) a genetic modification that decreases expression of an aerobic respiratory control regulatory system relative to the microbial organism in the absence of the genetic modification; (iii) a genetic modification that increases expression of an NADH insensitive citrate synthase relative to the microbial organism in the absence of the genetic modification; (iv) a genetic modification that decreases expression of malate dehydrogenase relative to the microbial organism in the absence of the genetic modification; (v) a genetic modification that decreases expression of lactate dehydrogenase relative to the microbial organism in the absence of the genetic modification; (vi) a genetic modification that decreases expression of pyruvate formate lyase relative to the microbial organism in the absence of the genetic modification; and (vii) a combination of two or more, three or more, four or more, five or all of the genetic modifications of parts (i)-(vi). 6. The microbial organism of claim 2 , wherein: (I) the microbial organism of part (A), (B) or (C) has decreased production of ethanol, acetate, pyruvate or alanine, or a combination thereof, relative to the microbial organism in the absence of said genetic modification; (J) the microbial organism of part (B) has decreased production of glutamate relative to the microbial organism in the absence of said genetic modification; (K) the microbial organism of part (C) has a genetic modification comprising increased expression of a permease, glucokinase, or a glucose facilitator, or a combination thereof relative to the microbial organism in the absence of said genetic modification; (L) the microbial organism of part (D) has increased production of 4-hydroxybutyrate relative to the microbial organism in the absence of said genetic modification; (M) the microbial organism of part (E) has decreased production of gamma-butyrolactone relative to the microbial organism in the absence of said genetic modification; (N) the microbial organism of part (E) has a genetic modification comprising at least two genetic modifications that decrease expression of at least two acyl coenzyme A thioesterases relative to the microbial organism in the absence of said genetic modification; (O) the microbial organism of part (F) has suppressed depletion of the NADH pool or increased energy efficiency in the microbial organism, or a combination thereof, relative to the microbial organism in the absence of said genetic modification; (P) the microbial organism of part (G) has increased energy efficiency relative to the microbial organism in the absence of said genetic modification; or (Q) the microbial organism of part (G) has increased tolerance to a range of oxygen concentrations relative to the microbial organism in the absence of said genetic modification. 7. A method for producing 4-hydroxybutyrate, comprising culturing the non-naturally occurring microbial organism of claim 1 under conditions and for a sufficient period of time to produce 4-hydroxybutyrate. 8. A method for producing 1,4-butanediol, comprising culturing the non-naturally occurring microbial organism of claim 4 under conditions and for a sufficient period of time to produce 1,4-butanediol. 9. A method for producing isolated or purified 4-hydroxybutyrate or 1,4-butanediol, comprising culturing the non-naturally occurring microbial organism of claim 4 under conditions and for a sufficient period of time to produce 4-hydroxybutyrate or 1,4-butanediol, and isolating or purifying the 4-hydroxybutyrate or 1,4-butanediol. 10. The method of claim 9 , wherein the isolating or purifying comprises distillation. 11. The microbial organism of claim 1 , wherein the microbial organism has decreased backflux from a downstream product of the 4-hydroxybutyrate pathway relative to the microbial organism in the absence of said genetic modification to decrease expression of an alcohol dehydrogenase.
Bacteria; Culture media therefor · CPC title
1,4-Butanediol; 1,3-Butanediol; 1,2-Butanediol; 2,3-Butanediol · CPC title
Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups · CPC title
Compounds containing ester groups, e.g. oxyalkylated monocarboxylic acids · CPC title
aliphatic · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.